Using a hormone treatment to lower breast cancer risk in women with hot flashes
Biomarker-Based Phase IIB Trial of (Bazedoxifene-Conjugated Estrogen) to Reduce Risk for Breast Cancer
This study is looking at how well a hormone treatment called Duavee® can help lower the risk of breast cancer in women who have hot flashes and are at higher risk for the disease, while also checking for any side effects and how it affects their overall well-being over six months.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-10922672 on NIH RePORTER |
What this research studies
This research investigates the use of a hormone treatment called Duavee®, which combines bazedoxifene and conjugated estrogen, to reduce the risk of breast cancer in women who experience hot flashes and are at high risk for the disease. The study aims to determine the effectiveness of this treatment over six months by measuring various health indicators, including blood markers and mammographic changes. Participants will be monitored for side effects and overall quality of life, providing valuable data on the treatment's safety and efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are women who are at high risk for breast cancer and are experiencing vasomotor symptoms such as hot flashes.
Not a fit: Patients who are not at high risk for breast cancer or do not experience menopausal symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective option for breast cancer risk reduction in women experiencing menopausal symptoms.
How similar studies have performed: Previous studies have shown promising results with similar hormone treatments in managing menopausal symptoms and reducing breast cancer risk, indicating potential for success in this trial.
Where this research is happening
Kansas City, United States
- University of Kansas Medical Center — Kansas City, United States (Active)
Researchers
- Principal investigator: Fabian, Carol J. — University of Kansas Medical Center
- Study coordinator: Fabian, Carol J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.